Characteristics of the 92 patients according to their PI3K/Akt status
| . | TotalN=92 . | PI3K + N=46 (50%) . | PI3K − N=46 (50%) . | P . |
|---|---|---|---|---|
| Mean age, y (SD) | 44 (12) | 45 (12) | 44 (12) | 0.82 |
| Male, N (%) | 41 (45) | 19 (42) | 22 (48) | 0.59 |
| Median WBC count, × 109/L (range) | 12 (0.4-252) | 8.6 (0.7-140) | 16.9 (0.4-252) | 0.12 |
| LDH over 400 UI/L, N (%) | 58 (81) | 31 (82) | 27 (79) | 0.82 |
| Tumor burden, N/total (%) | 31/77 (40) | 16/39 (41) | 15/38 (40) | 0.89 |
| % BM blasts, median (range) | 51 (0-100) | 70 (22-98) | 58 (0-100) | 0.13 |
| FAB, N (%) | ||||
| M0 | 9 (10) | 4 (9) | 5 (11) | — |
| M1 | 20 (22) | 9 (20) | 11 (24) | — |
| M2 | 32 (35) | 17 (37) | 15 (33) | — |
| M4 | 19 (21) | 8 (17) | 11 (25) | — |
| M5 | 11 (12) | 8 (17) | 3 (7) | 0.55 |
| Cytogenetic subgroup, N (%)* | ||||
| Unfavorable | 20 (23) | 7 (16) | 13 (30) | — |
| Intermediate | 54 (61) | 29 (66) | 25 (57) | — |
| Favorable | 14 (16) | 8 (18) | 6 (13) | 0.30 |
| MDS features, N (%) | 17 (19) | 9 (20) | 8 (17) | 0.79 |
| Mutations, N (%) | ||||
| FLT3-ITDpos | 17/79 (22) | 5/40 (13) | 12/39 (31) | 0.048 |
| RAS (N-RAS and K-RAS) | 9/60 (15) | 6/32 (19) | 3/28 (11) | 0.48 |
| NPM1-mut | 17/70 (24) | 8/33 (24) | 9/37 (24) | 0.99 |
| NPM1-wt/FLT3-ITDneg | 45/69 (64) | 23/33 (70) | 21/36 (58) | — |
| NPM1-mut/FLT3-ITDneg | 10/69 (13) | 5/33 (15) | 4/36 (11) | — |
| NPM1-wt/FLT3-ITDpos | 8/69 (12) | 2/33 (6) | 6/36 (17) | — |
| NPM1-mut/FLT3-ITDpos | 8/69 (12) | 3/33 (9) | 5/36 (14) | 0.51 |
| Outcome: CR, N (%) | 74 (80) | 38 (83) | 36 (78) | 0.59 |
| . | TotalN=92 . | PI3K + N=46 (50%) . | PI3K − N=46 (50%) . | P . |
|---|---|---|---|---|
| Mean age, y (SD) | 44 (12) | 45 (12) | 44 (12) | 0.82 |
| Male, N (%) | 41 (45) | 19 (42) | 22 (48) | 0.59 |
| Median WBC count, × 109/L (range) | 12 (0.4-252) | 8.6 (0.7-140) | 16.9 (0.4-252) | 0.12 |
| LDH over 400 UI/L, N (%) | 58 (81) | 31 (82) | 27 (79) | 0.82 |
| Tumor burden, N/total (%) | 31/77 (40) | 16/39 (41) | 15/38 (40) | 0.89 |
| % BM blasts, median (range) | 51 (0-100) | 70 (22-98) | 58 (0-100) | 0.13 |
| FAB, N (%) | ||||
| M0 | 9 (10) | 4 (9) | 5 (11) | — |
| M1 | 20 (22) | 9 (20) | 11 (24) | — |
| M2 | 32 (35) | 17 (37) | 15 (33) | — |
| M4 | 19 (21) | 8 (17) | 11 (25) | — |
| M5 | 11 (12) | 8 (17) | 3 (7) | 0.55 |
| Cytogenetic subgroup, N (%)* | ||||
| Unfavorable | 20 (23) | 7 (16) | 13 (30) | — |
| Intermediate | 54 (61) | 29 (66) | 25 (57) | — |
| Favorable | 14 (16) | 8 (18) | 6 (13) | 0.30 |
| MDS features, N (%) | 17 (19) | 9 (20) | 8 (17) | 0.79 |
| Mutations, N (%) | ||||
| FLT3-ITDpos | 17/79 (22) | 5/40 (13) | 12/39 (31) | 0.048 |
| RAS (N-RAS and K-RAS) | 9/60 (15) | 6/32 (19) | 3/28 (11) | 0.48 |
| NPM1-mut | 17/70 (24) | 8/33 (24) | 9/37 (24) | 0.99 |
| NPM1-wt/FLT3-ITDneg | 45/69 (64) | 23/33 (70) | 21/36 (58) | — |
| NPM1-mut/FLT3-ITDneg | 10/69 (13) | 5/33 (15) | 4/36 (11) | — |
| NPM1-wt/FLT3-ITDpos | 8/69 (12) | 2/33 (6) | 6/36 (17) | — |
| NPM1-mut/FLT3-ITDpos | 8/69 (12) | 3/33 (9) | 5/36 (14) | 0.51 |
| Outcome: CR, N (%) | 74 (80) | 38 (83) | 36 (78) | 0.59 |
Differences between groups were tested for categorical variables using the χ2 test or the Fisher exact test, when appropriate. Differences between groups for continuous variables were tested using the Student test or the Wilcoxon rank-sum test, when appropriate.
CR indicates complete remission; FAB, French-American-British classification; FLT3-ITD, Internal Tandem Duplication of the FLT3 receptor; WBC, white blood cell; SD, standard deviation; and —, not applicable.
Cytogenetic subgroups: karyotype risk groups were defined according to the SWOG criteria.